Arcus Biosciences (RCUS) EBT Margin Growth (3y) (2020 - 2026)

Arcus Biosciences (RCUS) EBT Margin Growth (3y) (2020 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Margin Growth (3y) (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -484.00
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 132.00
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -674,462.00
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 8,006.00
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 71,157.00
7 Royalty Pharma 33.72 Bn 35.84 Bn - -5,319.00
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 9,980.00
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 31,363.00
10 Arcus Biosciences 3.74 Bn 3.04 Bn - 3,322.00

Historic Data

Download Data
DateValue
Jun 30, 2026 3,322.00
Mar 31, 2026 -44,094.00
Dec 31, 2025 -12,415.00
Sep 30, 2025 -32,226.00
Mar 31, 2025 -2,778.00
Dec 31, 2024 -43,708.00
Sep 30, 2024 63,251.00
Jun 30, 2024 56,452.00
Mar 31, 2024 76,453.00
Dec 31, 2023 -163.00
Sep 30, 2023 -21,845.00
Jun 30, 2023 232,048.00
Mar 31, 2023 127,389.00
Dec 31, 2022 -205.00
Sep 30, 2022 105,989.00
Jun 30, 2022 133,345.00
Mar 31, 2022 61,286.00
Dec 31, 2021 281,371.00
Sep 30, 2021 -57,654.00
Jun 30, 2021 36,590.00